HbA1c and biomarkers of diabetes mellitus in Clinical Chemistry and Laboratory Medicine : ten years after
© 2022 Walter de Gruyter GmbH, Berlin/Boston..
Since its discovery in the late 1960s, HbA1c has proven to be a major biomarker of diabetes mellitus survey and diagnosis. Other biomarkers have also been described using classical laboratory methods or more innovative, non-invasive ones. All biomarkers of diabetes, including the historical glucose assay, have well-controlled strengths and limitations, determining their indications in clinical use. They all request high quality preanalytical and analytical methodologies, necessitating a strict evaluation of their performances by external quality control assessment trials. Specific requirements are needed for point-of-care testing technologies. This general overview, which describes how old and new tools of diabetes mellitus biological survey have evolved over the last decade, has been built through the prism of papers published in Clinical Chemistry and Laboratory Medicine during this period.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 61(2023), 5 vom: 25. Apr., Seite 861-872 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gillery, Philippe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 03.04.2023 Date Revised 05.04.2023 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1515/cclm-2022-0894 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347547257 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347547257 | ||
| 003 | DE-627 | ||
| 005 | 20231226034101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2022-0894 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347547257 | ||
| 035 | |a (NLM)36239682 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gillery, Philippe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HbA1c and biomarkers of diabetes mellitus in Clinical Chemistry and Laboratory Medicine |b ten years after |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2023 | ||
| 500 | |a Date Revised 05.04.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 Walter de Gruyter GmbH, Berlin/Boston. | ||
| 520 | |a Since its discovery in the late 1960s, HbA1c has proven to be a major biomarker of diabetes mellitus survey and diagnosis. Other biomarkers have also been described using classical laboratory methods or more innovative, non-invasive ones. All biomarkers of diabetes, including the historical glucose assay, have well-controlled strengths and limitations, determining their indications in clinical use. They all request high quality preanalytical and analytical methodologies, necessitating a strict evaluation of their performances by external quality control assessment trials. Specific requirements are needed for point-of-care testing technologies. This general overview, which describes how old and new tools of diabetes mellitus biological survey have evolved over the last decade, has been built through the prism of papers published in Clinical Chemistry and Laboratory Medicine during this period | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Clinical Chemistry and Laboratory Medicine | |
| 650 | 4 | |a HbA1c | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a glycation | |
| 650 | 4 | |a point-of-care testing | |
| 650 | 7 | |a Glycated Hemoglobin |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d 1998 |g 61(2023), 5 vom: 25. Apr., Seite 861-872 |w (DE-627)NLM095304118 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2023 |g number:5 |g day:25 |g month:04 |g pages:861-872 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/cclm-2022-0894 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2023 |e 5 |b 25 |c 04 |h 861-872 | ||